0000950170-23-022775.txt : 20230517
0000950170-23-022775.hdr.sgml : 20230517
20230517165842
ACCESSION NUMBER: 0000950170-23-022775
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230515
FILED AS OF DATE: 20230517
DATE AS OF CHANGE: 20230517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yeramian Patrick D
CENTRAL INDEX KEY: 0001358266
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 23932571
MAIL ADDRESS:
STREET 1: 1815 PARKSIDE CIRCLE SOUTH
CITY: BOCA RATON
STATE: FL
ZIP: 33486
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
ownership.xml
4
X0407
4
2023-05-15
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001358266
Yeramian Patrick D
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
false
true
false
false
Chief Medical Officer
true
Common Stock
2023-05-15
4
M
false
2201
0.37
A
210618
D
Common Stock
2023-05-15
4
M
false
9764
6.88
A
220382
D
Common Stock
2023-05-15
4
S
false
11965
29.0312
D
208417
D
Stock Option (right to buy)
0.37
2023-05-15
4
M
false
2201
0
D
2029-03-18
Common Stock
2201
15404
D
Stock Option (right to buy)
6.88
2023-05-15
4
M
false
9764
0
D
2031-02-21
Common Stock
9764
33770
D
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
As of the date of this filing, 2,201 shares subject to the option are vested and exercisable. 15,404 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
As of the date of this filing, 13,746 shares subject to the option are vested and exercisable. 23,600 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.
/s/ Joshua B. Cohen, as Attorney in Fact
2023-05-17